Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02273375 · ClinicalTrials.gov registry record · Phase 3
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Canadian Cancer Trials Group.
- Active
- Registry status
- Phase 3
- Development phase
- 1,415
- Enrollment target
- 20
- Study locations
NCT02273375: Active Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Canadian Cancer Trials Group.
NCT02273375 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Canadian Cancer Trials Group. The registered enrollment target is 1,415 participants, above the 649-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (118% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02273375, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Canadian Cancer Trials Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,415 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MEDI4736
Study Locations (20)
New South Wales
- Campbelltown Hospital - Campbelltown
- Chris O'Brien Lifehouse - Camperdown
- Coffs Habour Health Campus - NCCI - Coffs Harbour
- Gosford Hospital - Gosford
- Nepean Hospital - Kingswood
- St. George Hospital, Cancer Care Centre - Kogarah
- Liverpool Cancer Therapy Centre, Liverpool Hospital - Liverpool
- Northern Cancer Institute St Leonards - St Leonards
- Westmead Hospital - Westmead
Pennsylvania
- Hematology and Oncology Associates of NEPA - Dunmore
- Thomas Jefferson University - Philadelphia
- The Reading Hospital Medical Center - West Reading
Florida
- University of Florida - Gainesville
- H. Lee Moffitt Cancer Center - Tampa
Queensland
- Sunshine Coast University Hospital - Birtinya
- Princess Alexandra Hospital - Brisbane
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- USC Norris/Comprehensive Cancer Centre - Los Angeles
Colorado
- National Jewish Health - Denver
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,415 participants |
| Start Date | 2015-02-24 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 3 |
What the registry record for NCT02273375 still lists
NCT02273375 is an interventional study that assigns participants to a tested intervention. Its 1,415 participants enrollment target places it among the larger protocols in the corpus, above the 649-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (118% higher).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02273375 names 20 study sites across 8 states, led by New South Wales, Pennsylvania, Florida.
Frequently Asked Questions
What is clinical trial NCT02273375 about?
NCT02273375 is a clinical study titled "Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC". The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
What is the current status of trial NCT02273375?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,415 participants. The study started on 2015-02-24. Estimated completion is 2026-01-31.
What conditions does trial NCT02273375 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02273375?
The interventions under investigation include: Placebo (DRUG), MEDI4736 (DRUG).
Who is sponsoring clinical trial NCT02273375?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02273375 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02273375's enrollment target sits among peer trials
1,415 12th of 454 higher than 443 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
- NCT05444582 · 1,404 participants · Phase 4
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI